August 21, 2016
 · 
1 min read

Tagworks paper on triggered drug release in Bioconjugate Chemistry

In a recent publication in the scientific journal Bioconjugate Chemistry, Tagworks Pharma describes its success in using a bioorthogonal reaction for the selective cleavage of tumor-bound ADCs in mice. This represents a powerful new tool for ADC therapy as it does not rely on the currently used biological activation mechanisms, thereby potentially expanding the scope of ADC therapy to noninternalizing cancer targets.

Read the full paper - doi:10.1021/acs.bioconjchem.6b00231

 

Curious about what we do? Get in touch!

Logo-diap

About    Our Technology   Pipeline    Join us    News    Contact

Contact
T +31 85 800 8550
info@tagworkspharma.com

Address
Tagworks Pharmaceuticals BV
Toernooiveld 1
6525 ED  Nijmegen
The Netherlands

Stay updated

© Tagworks Pharmaceuticals, 2024 | Terms of use | Design by Ape to Zebra